Clinical Trial Update: Low-Dose Azacitidine, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating low-dose azacitidine, lenalidomide, and low-dose dexamethasone in relapsed or refractory multiple myeloma has completed with results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• DEXAMETHASONE (Dexamethasone)
• Lenalidomide (lenalidomide)

Snippet

Sponsor: Case Comprehensive Cancer Center | Conditions: Refractory Multiple Myeloma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2020-10-12